Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.78
-0.04 (-2.20%)
Market open: Aug 12, 2026, 10:12 AM EDT
1.81
-0.01 (-0.55%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
| Name | Position |
|---|---|
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. William J. Grossman M.D., Ph.D. | Interim Chief Medical Officer & Director |
| Mr. Matthew Boyd | Chief Regulatory Officer |
| Mr. Ronald H. W. Cooper | President, CEO & Director |
| Ms. Amy Pott | Chief Global Commercialization Officer |
| Ms. Jill Buck | Chief Development Officer |
| Ms. Joan Connolly | Chief Technology Officer |
| Ms. Kathleen Richton | Senior VP of Finance, Principal Accounting & Financial Officer and Controller |
| Ms. Tara Place M.B.A. | Senior VP of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-07-17 | 8-K | engn-20260717.htm |
| 2026-07-16 | 8-K | engn-20260715.htm |
| 2026-06-18 | 8-K/A | engn-20260616.htm |
| 2026-06-15 | 8-K | engn-20260613.htm |
| 2026-06-15 | 10-Q | engn-20260430.htm |
| 2026-06-10 | 8-K | engn-20260609.htm |
| 2026-05-08 | DEF 14A | ef20072046_def14a.htm |
| 2026-05-08 | ARS | ef20072042_ars.pdf |
| 2026-05-07 | 8-K | d335486d8k.htm |
| 2026-04-09 | 8-K | engn-20260407.htm |